COVID-19 vaccine development: milestones, lessons and prospects
M Li, H Wang, L Tian, Z Pang, Q Yang… - Signal transduction and …, 2022 - nature.com
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
SARS-CoV-2 variants, vaccines, and host immunity
P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
AR Falsey, ME Sobieszczyk, I Hirsch… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis
Background Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new
syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe …
syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …
progressive change, with variants conferring advantage rapidly becoming dominant …
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England …
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including …
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including …
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK …
ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
[HTML][HTML] Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
Summary Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca
(ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase …
(ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase …